anp chart, page-926

@chilusin

I strongly believe there will be a deal pre the trial results. They have repeatedly said they are not taking the drug to market. There is also the risk of having to do a P3, but I think this is low.

It will be a decent upfront >US$100m to US$300m which allows management to pursue the pipeline.

Milestones will be favourable but not crazy (ie $500m) BUT the royalty will be sizeable. This is where the cream is!!

The potential of ATL1102 in both non ambulant and the ambulant population is unknown but probably much more significant in both the price of the drug (ANP stating minimum US$200k, but could be much higher) and the number of boys, so this allows both parties to share the upside and the risk.

I have previously stated this could happen before Xmas. It is possible but more likely Q1 next year. Management have stated (also repeatedly) that a deal is not reliant on tox data but the 9 months of dosing ends mid November so they will have this data in hand by January at latest. NDA’s with potential partners would allow this to be shared well before they are obligated to announce it to the market.

Almost mid October so significant news milestones not far away now.